Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
The objective of this case report was to review and point out a new pattern of immune checkpoint inhibitor-associated pneumonitis.
Case Description: A 69-year-old woman with stage iv non-small-cell lung cancer receiving pembrolizumab presented for increased dyspnea. Pembrolizumab-related obstructive bronchiolitis was diagnosed based on a new severe obstructive disorder, without bronchodilator reversibility, and mosaic attenuation on angiography, without other identifiable causes.
Summary: To our knowledge, this is the first description of a case of pembrolizumab-induced obstructive bronchiolitis. Various patterns of immune checkpoint inhibitor-associated lung disease have been described, and bronchiolitis should be included in the differential diagnosis.
PMID: 31548826 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Angiography | Bronchiolitis | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer